A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
05
08
2021
accepted:
15
11
2021
revised:
05
11
2021
pubmed:
11
1
2022
medline:
7
4
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
Despite the recent progress, multiple myeloma (MM) is still essentially incurable and there is a need for additional effective treatments with good tolerability. RO7297089 is a novel bispecific BCMA/CD16A-directed innate cell engager (ICE
Identifiants
pubmed: 35001074
doi: 10.1038/s41375-021-01478-w
pii: 10.1038/s41375-021-01478-w
doi:
Substances chimiques
Antibodies, Bispecific
0
B-Cell Maturation Antigen
0
Receptors, IgG
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1006-1014Subventions
Organisme : NIGMS NIH HHS
ID : P41 GM103393
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Laubach JP, Paba Prada CE, Richardson PG, Longo DL. Daratumumab, elotuzumab, and the development of therapeutic monoclonal antibodies in multiple myeloma. Clin Pharm Ther. 2017;101:81–8.
doi: 10.1002/cpt.550
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.
doi: 10.1056/NEJMoa043445
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–17.
doi: 10.1056/NEJMoa0801479
Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther. 2019;19:1143–56.
doi: 10.1080/14712598.2019.1641196
Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821.
doi: 10.3389/fimmu.2018.01821
DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, et al. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021;5:1291–304.
doi: 10.1182/bloodadvances.2020002736
Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38:775–83.
doi: 10.1200/JCO.19.02657
Barilà G, Rizzi R, Zambello R, Musto P. Drug conjugated and bispecific antibodies for multiple myeloma: improving immunotherapies off the shelf. Pharmaceuticals. 2021;14:40.
doi: 10.3390/ph14010040
Zhou X, Rasche L, Kortüm KM, Danhof S, Hudecek M, Einsele H. Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: an overview of experience from clinical trials, pathophysiology, and management strategies. Front Immunol. 2020;11:620312.
doi: 10.3389/fimmu.2020.620312
Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136:2401–9.
doi: 10.1182/blood.2019004701
Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, et al. Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther. 2013;21:895–903.
doi: 10.1038/mt.2013.14
Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:4024–31.
doi: 10.1182/blood-2014-12-614636
Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells. MAbs. 2014;6:727–38.
doi: 10.4161/mabs.28591
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–8.
doi: 10.1182/blood.V99.3.754
Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26:1789–96.
doi: 10.1200/JCO.2007.14.8957
Casneuf T, Xu XS, Adams HC 3rd, Axel AE, Chiu C, Khan I, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1:2105–14.
doi: 10.1182/bloodadvances.2017006866
Ellwanger K, Reusch U, Fucek I, Wingert S, Ross T, Müller T, et al. Redirected optimized cell killing (ROCK®): a highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity. MAbs. 2019;11:899–918.
doi: 10.1080/19420862.2019.1616506
Alaterre E, Raimbault S, Garcia JM, Rème T, Requirand G, Klein B, et al. Automated and simplified identification of normal and abnormal plasma cells in multiple myeloma by flow cytometry. Cytom B Clin Cytom. 2018;94:484–92.
doi: 10.1002/cyto.b.21590
Kay B, Winter J, McCafferty J. Phage display of peptides and proteins. San Diego, CA, USA: Academic Press; 1996.
Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res. 2005;11:2327–36.
doi: 10.1158/1078-0432.CCR-04-2263
Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994;180:1395–403.
doi: 10.1084/jem.180.4.1395
Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90:1109–14.
doi: 10.1182/blood.V90.3.1109
Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Investig. 1997;100:1059–70.
doi: 10.1172/JCI119616
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.
doi: 10.4065/78.1.21
Patel DR, Wallweber HJA, Yin J, Shriver SK, Marsters SA, Gordon NC, et al. Engineering an APRIL-specific B cell maturation antigen. J Biol Chem. 2004;279:16727–35.
doi: 10.1074/jbc.M312316200
Chen H, Li M, Xu N, Ng N, Sanchez E, Soof CM, et al. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leuk Res. 2019;81:62–6.
doi: 10.1016/j.leukres.2019.04.008
Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102:785–95.
doi: 10.3324/haematol.2016.150896
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641–53.
doi: 10.1016/S1470-2045(18)30576-X
Goyos A, Li C-M, Deegen P, Bogner P, Thomas O, Wahl J, et al. Abstract LB-299: Cynomolgus monkey plasma cell gene signature to quantify thein vivoactivity of a half-life extended anti-BCMA BiTE® for the treatment of multiple myeloma. Cancer Res. 2018;78:LB-299.
Castro CD, Flajnik MF. Putting J chain back on the map: how might its expression define plasma cell development? J Immunol. 2014;193:3248–55.
doi: 10.4049/jimmunol.1400531
van de Donk N, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, et al. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. Br J Haematol. 2019;184:475–9.
doi: 10.1111/bjh.15122
Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br J Cancer. 1998;78:478–83.
doi: 10.1038/bjc.1998.518
Wang Y, Zhang Y, Hughes T, Zhang J, Caligiuri MA, Benson DM, et al. Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells. Clin Cancer Res. 2018;24:4006–17.
doi: 10.1158/1078-0432.CCR-17-3117
Lamb YN. Elotuzumab: a review in relapsed and/or refractory multiple myeloma. Drugs. 2018;78:1481–8.
doi: 10.1007/s40265-018-0969-4
Plesner T, Krejcik J. Daratumumab for the treatment of multiple myeloma. Front Immunol. 2018;9:1228.
doi: 10.3389/fimmu.2018.01228
Liu P, Jin Y, Sattar H, Liu H, Xie W, Zhou F. Natural killer cell immunotherapy against multiple myeloma: progress and possibilities. J Leukoc Biol. 2018;103:821–8.
doi: 10.1002/JLB.2RU0517-176RR
Luna JI, Grossenbacher SK, Sturgill IR, Ames E, Judge SJ, Bouzid LA, et al. Bortezomib augments natural killer cell targeting of stem-like tumor cells. Cancers. 2019;11:85.
doi: 10.3390/cancers11010085